Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Tarih
2018
Yazar
MAYO, Carlos
CHUNG, Hyun C.
MURO, Kei
Goekkurt, Eray
MANSOOR, Wasat
MCDERMOTT, Raymond S.
SHACHAM-SHMUELI, Einat
CHEN, Xinqun
KANG, S. Peter
OHTSU, Atsushi
Fuchs, Charles S.
SHITARA, Kohei
BANG, Yung-Jue
DI BARTOLOMEO, Maria
MANDALA, Mario
RYU, Min-Hee
FORNARO, Lorenzo
OLESINSKI, Tomasz
CAGLEVIC, Christian
Ozguroglu, Mustafa
Üst veri
Tüm öğe kaydını göster
Özet
Background Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastrooesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.
Bağlantı
http://hdl.handle.net/20.500.12627/140282
https://doi.org/10.1016/s0140-6736(18)31257-1
Koleksiyonlar